维甲酸诱导蛋白6抗体
规格：1尘驳/1尘濒
英文名： STRA6
别名： Stimulated by retinoic acid gene 6 protein homolog; STRA6_HUMAN.
分子量： 74kDa
储存液：0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glyce
克隆类型：笔辞濒测肠濒辞苍补濒
亚型：滨驳骋
纯化方法：affinity purified by Protein A
**原：KLH conjugated synthetic peptide derived from Human STRA6
交叉反应：Human, Mouse, Rat, Dog, Horse, Rabbit,
细胞定位：细胞膜
维甲酸诱导蛋白6抗体产物介绍：background: STRA6 is a 667 amino acid, multi-pass cell membrane protein. Stra6 functions as a cell-surface receptor for the complex retinol-retinol binding protein (RBP/RBP4). Ultimately increasing cellular retinol uptake from the retinol-RBP complex, Stra6 removes retinol from RBP/RPB4 and transports it across the plasma membrane, where it is metabolized. Stra6 is broadly expressed, with 4 named isoforms that exist as a result of alternative splicing events. Mutations in the gene encoding Stra6 cause Matthew-Wood Syndrome, also known as Spear Syndrome. This syndrome is characterized by anophtalmia, mild facial dysmorphism and malformations of the heart, lung and diaphragm. The Stra6 gene maps to chromosome 15q24.1. Function: Stra6 functions as a high-affinity cell-surface receptor for the complex retinol-retinol binding protein (RBP/RBP4). Stra6 is expressed in the extraembryonic endoderm and expression is also known to be induced by Wnt1. Defects in维甲酸诱导蛋白6抗体 STRA6 are known to cause of syndromic microphthalmia type 9 (MCOPS9) also known as clinical anophthalmia with mild facial dysmorphism and variable malformations of the lung, heart, and diaphragm or anophthalmia/microphthalmia and pulmonary hypoplasia or Spear syndrome or Matthew-Wood syndrome or pulmonary agenesis, microphthalmia, and diaphragmatic defect. Subcellular Location: Cell membrane; multi-pass membrane protein. Tissue Specificity: Broad expression. In eye expressed in sclera, retina, retinal pigment epithelium, and trabecular meshwork but not in choroid and iris. DISEASE: Defects in STRA6 are the cause of microphthalmia syndromic type 9 (MCOPS9) [MIM:601186]; also called Matthew-Wood syndrome or Spear syndrome. Microphthalmia is a clinically heterogeneous disorder of eye formation, ranging from small size of 维甲酸诱导蛋白6抗体a single eye to complete bilateral absence of ocular tissues (anophthalmia). In many cases, microphthalmia/anophthalmia occurs in association with syndromes that include non-ocular abnormalities. MCOPS9 is a rare clinical entity including as main characteristics anophthalmia or severe microphthalmia, and pulmonary hypoplasia or aplasia. Note=Mutations in STRA6 may be a cause of isolated colobomatous microphthalmia, a disorder of the eye characterized by an abnormally small ocular globe. Database links: UniProtKB/Swiss-Prot: Q9BX79.1 Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
维甲酸诱导蛋白6抗体产物应用：ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 （石蜡切片需做抗原修复） not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user.
研究领域：肿瘤 细胞生物 信号转导 细胞类型标志物 新陈代谢
储存条件： Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.
来源： Rabbit